To determine whether MS-275 enhances ACT by selectively increasing the total number of tumor-infiltrating CD8+ T cells, we stained tumor sections with anti-CD8 antibody for immunohistochemical analysis 5 days after treatment. This evidence concerns the gene CD8A and neoplasm.